NEUROMYELITIS OPTICA

Clinical trials for NEUROMYELITIS OPTICA explained in plain language.

Never miss a new study

Get alerted when new NEUROMYELITIS OPTICA trials appear

Sign up with your email to follow new studies for NEUROMYELITIS OPTICA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 3 Completed 1 Terminated 1

New drug shows promise in reducing NMOSD attacks

Disease control Completed

This study tested a drug called ravulizumab in 58 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the nerves and spinal cord. The goal was to see if the drug could prevent or reduce relapses (sudden worsening of symptoms). Pa…

Matched conditions: NEUROMYELITIS OPTICA

Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated May 17, 2026 02:44 UTC

NEUROMYELITIS OPTICA

Get alerted when new NEUROMYELITIS OPTICA trials appear

New drug shows promise in reducing NMOSD attacks